|Bid||2.71 x 100|
|Ask||2.87 x 1300|
|Day's Range||2.71 - 2.89|
|52 Week Range||1.82 - 7.69|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Investors in Sunesis Pharmaceuticals (SNSS) need to pay close attention to the stock based on moves in the options market lately.
The South San Francisco, California-based company said it had a loss of 21 cents per share. For the year, the company reported that its loss narrowed to $35.5 million, or $1.45 per share. Revenue was reported ...
On Thursday, Sunesis Pharmaceuticals (NASDAQ: SNSS ) will report its last quarter's earnings. Here is Benzinga's take on the company's release. Earnings and Revenue Sunesis Pharmaceuticals EPS loss will ...
Measuring Sunesis Pharmaceuticals Inc’s (NASDAQ:SNSS) track record of past performance is an insightful exercise for investors. It enables us to reflect on whether the company has met or exceed expectations,Read More...
The South San Francisco, California-based company said it had a loss of 43 cents per share. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...
Zacks.com featured highlights include MINDBODY, TearLab, Sunesis Pharmaceuticals, Children's Place, Franklin Electric
The South San Francisco, California-based company said it had a loss of 41 cents per share. The company's shares closed at $2.69. A year ago, they were trading at $3.01. _____ This story was generated ...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Sunesis Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to SNSS-US. Comparing the performance and risk of Sunesis Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Categories: Yahoo FinanceGet free summary analysis Sunesis Pharmaceuticals, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Sunesis Pharmaceuticals, Inc. – Spectrum Pharmaceuticals, Inc., Seattle Genetics, Inc., Celgene Corporation and Biogen Inc. (SPPI-US, SGEN-US, CELG-US and BIIB-US) that have also reported for this period. Highlights ... Read more (Read more...)
The South San Francisco, California-based company said it had a loss of 47 cents per share. The biopharmaceutical company posted revenue of $669,000 in the period. The company's shares closed at $3.11. ...